SCHEMBL21597675

SCHEMBL21597675

CNC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 2/20 0.48
FLT3 P36888 1/20 0.47
CNR2 P34972 3/20 0.44
CNR1 P21554 1/20 0.44
REV1 Q9UBZ9 1/20 0.43
RAB9A P51151 4/20 0.41
POLB P06746 2/20 0.41
ALDH1A1 P00352 5/20 0.40
NPC1 O15118 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 3/20 0.39
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597756 0.86 FLT3 (0.50) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597638 0.85 KDM4E (0.67) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL5445103 0.85 FLT3 (0.66) MAPTKDM4EHSD17B10FLT3REV1
SCHEMBL21597594 0.81 ALDH1A1 (0.61) MAPTKDM4EHSD17B10RAB9APOLB
SCHEMBL5453482 0.81 MAPT (0.72) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597081 0.78 MAPT (0.48) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597509 0.78 MAPT (0.48) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL27415543 0.77 KDM4E (0.47) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL3803667 0.76 CNR2 (0.68) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597119 0.72 REV1 (0.53) MAPTKDM4EHSD17B10FLT3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885KDM4E 3965/4885HSD17B10 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.